Organoid modeling for cancer precision medicine

Michael A Cantrell,Calvin J Kuo

DOI: https://doi.org/10.1186/s13073-015-0158-y

IF: 15.266

2015-03-31

Genome Medicine

Abstract:Editorial summaryThree-dimensional organotypic culture models show great promise as a tool for cancer precision medicine, with potential applications for oncogene modeling, gene discovery and chemosensitivity studies.

genetics & heredity

What problem does this paper attempt to address?

Cancer modeling meets human organoid technology

David Tuveson,Hans Clevers

DOI: https://doi.org/10.1126/science.aaw6985

IF: 56.9

2019-06-07

Science

Abstract:Organoids are microscopic self-organizing, three-dimensional structures that are grown from stem cells in vitro. They recapitulate many structural and functional aspects of their in vivo counterpart organs. This versatile technology has led to the development of many novel human cancer models. It is now possible to create indefinitely expanding organoids starting from tumor tissue of individuals suffering from a range of carcinomas. Alternatively, CRISPR-based gene modification allows the engineering of organoid models of cancer through the introduction of any combination of cancer gene alterations to normal organoids. When combined with immune cells and fibroblasts, tumor organoids become models for the cancer microenvironment enabling immune-oncology applications. Emerging evidence indicates that organoids can be used to accurately predict drug responses in a personalized treatment setting. Here, we review the current state and future prospects of the rapidly evolving tumor organoid field.

multidisciplinary sciences
Cancer organoid co-culture model system: Novel approach to guide precision medicine

Jin Yuan,Xiaoyang Li,Shengji Yu

DOI: https://doi.org/10.3389/fimmu.2022.1061388

IF: 7.3

2023-01-13

Frontiers in Immunology

Abstract:Three-dimensional cancer organoids derived from self-organizing cancer stems are ex vivo miniatures of tumors that faithfully recapitulate their structure, distinctive cancer features, and genetic signatures. As novel tools, current cancer organoids have been well established and rapidly applied in drug testing, genome editing, and transplantation, with the ultimate aim of entering clinical practice for guiding personalized therapy. However, given that the lack of a tumor microenvironment, including immune cells and fibrous cells, is a major limitation of this emerging methodology, co-culture models inspire high hope for further application of this technology in cancer research. Co-culture of cancer organoids and immune cells or fibroblasts is available to investigate the tumor microenvironment, molecular interactions, and chimeric antigen receptor-engineered lymphocytes in cancer treatment. In light of the recent progress in cancer organoid co-culture models, it is only possible to recognize the advantages and drawbacks of this novel model to exploit its full potential. In this review, we summarize the recent advances in the application of cancer organoids and co-culture models and how they could be improved in the future to benefit cancer research, especially precision medicine.

immunology
The power and the promise of organoid models for cancer precision medicine with next-generation functional diagnostics and pharmaceutical exploitation

Yu-Shui Ma,Xiao-Li Yang,Rui Xin,Ting-Miao Wu,Yi Shi,Dan Dan Zhang,Hui-Min Wang,Pei-Yao Wang,Ji-Bin Liu,Da Fu

DOI: https://doi.org/10.1016/j.tranon.2021.101126

IF: 4.803

2021-08-01

Translational Oncology

Abstract:As organ-specific three-dimensional cell clusters derived from cancer tissue or cancer-specific stem cells, cancer-derived organoids are organized in the same manner of the cell sorting and spatial lineage restriction in vivo, making them ideal for simulating the characteristics of cancer and the heterogeneity of cancer cells in vivo. Besides the applications as a new in vitro model to study the physiological characteristics of normal tissues and organs, organoids are also used for in vivo cancer cell characterization, anti-cancer drug screening, and precision medicine. However, organoid cultures are not without limitations, i.e., the lack of nerves, blood vessels, and immune cells. As a result, organoids could not fully replicate the characteristics of organs but partially simulate the disease process. This review attempts to provide insights into the organoid models for cancer precision medicine.<ol class="links-for-figure"><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S1936523321001182-fx1_lrg.jpg">Download : Download high-res image (88KB)</a></li><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S1936523321001182-fx1.jpg">Download : Download full-size image</a></li></ol>

oncology
Organoid co-culture models of the tumor microenvironment promote precision medicine

Zhaoru Gu,Quanyou Wu,Bingqing Shang,Kaitai Zhang,Wen Zhang

DOI: https://doi.org/10.1002/cai2.101

2023-12-17

Abstract:In recent years, the three-dimensional (3D) culture system has emerged as a promising preclinical model for tumor research owing to its ability to replicate the tissue structure and molecular characteristics of solid tumors in vivo. This system offers several advantages, including high throughput, efficiency, and retention of tumor heterogeneity. Traditional Matrigel-submerged organoid cultures primarily support the long-term proliferation of epithelial cells. One solution for the exploration of the tumor microenvironment is a reconstitution approach involving the introduction of exogenous cell types, either in dual, triple or even multiple combinations. Another solution is a holistic approach including patient-derived tumor fragments, air-liquid interface, suspension 3D culture, and microfluidic tumor-on-chip models. Organoid co-culture models have also gained popularity for studying the tumor microenvironment, evaluating tumor immunotherapy, identifying predictive biomarkers, screening for effective drugs, and modeling infections. By leveraging these 3D culture systems, it is hoped to advance the clinical application of therapeutic approaches and improve patient outcomes.
Organoids: approaches and utility in cancer research

Bingrui Zhou,Zhiwei Feng,Jun Xu,Jun Xie

DOI: https://doi.org/10.1097/cm9.0000000000002477

IF: 6.133

2023-06-27

Chinese Medical Journal

Abstract:ABSTRACT: Organoids are three-dimensional cellular structures with self-organizing and self-differentiation capacities. They faithfully recapitulate structures and functions of in vivo organs as represented by functionality and microstructural definitions. Heterogeneity in in vitro disease modeling is one of the main reasons for anti-cancer therapy failures. Establishing a powerful model to represent tumor heterogeneity is crucial for elucidating tumor biology and developing effective therapeutic strategies. Tumor organoids can retain the original tumor heterogeneity and are commonly used to mimic the cancer microenvironment when co-cultured with fibroblasts and immune cells; therefore, considerable effort has been made recently to promote the use of this new technology from basic research to clinical studies in tumors. In combination with gene editing technology and microfluidic chip systems, engineered tumor organoids show promising abilities to recapitulate tumorigenesis and metastasis. In many studies, the responses of tumor organoids to various drugs have shown a positive correlation with patient responses. Owing to these consistent responses and personalized characteristics with patient data, tumor organoids show excellent potential for preclinical research. Here, we summarize the properties of different tumor models and review their current state and progress in tumor organoids. We further discuss the substantial challenges and prospects in the rapidly developing tumor organoid field.

medicine, general & internal
Organoids for Cancer Research: Advances and Challenges

Miaomaio Xin,Qian Li,Dongyang Wang,Zheng Wang

DOI: https://doi.org/10.1002/adbi.202400056

2024-01-01

Advanced Biology

Abstract:As 3D culture technology advances, new avenues have opened for the development of physiological human cancer models. These preclinical models provide efficient ways to translate basic cancer research into clinical tumor therapies. Recently, cancer organoids have emerged as a model to dissect the more complex tumor microenvironment. Incorporating cancer organoids into preclinical programs have the potential to increase the success rate of oncology drug development and recapitulate the most efficacious treatment regimens for cancer patients. In this review, four main types of cancer organoids are introduced, their applications, advantages, limitations, and prospects are discussed, as well as the recent application of single-cell RNA-sequencing (scRNA-seq) in exploring cancer organoids to advance this field. The 3D cancer organoid, a model to dissect the complex tumor microenvironment, enables ex vivo analysis of in vivo tumors accurately. Currently, four main types of cancer organoids are classified with their advantages and disadvantages. The incorporation of cancer organoids into preclinical programs could increase the success rate of oncology drug development and treatment regimens for cancer patients. image
Tumor organoids: applications in cancer modeling and potentials in precision medicine

Hanxiao Xu,Dechao Jiao,Aiguo Liu,Kongming Wu

DOI: https://doi.org/10.1186/s13045-022-01278-4

2022-05-13

Abstract:Cancer is a top-ranked life-threatening disease with intratumor heterogeneity. Tumor heterogeneity is associated with metastasis, relapse, and therapy resistance. These factors contribute to treatment failure and an unfavorable prognosis. Personalized tumor models faithfully capturing the tumor heterogeneity of individual patients are urgently needed for precision medicine. Advances in stem cell culture have given rise to powerful organoid technology for the generation of in vitro three-dimensional tissues that have been shown to more accurately recapitulate the structures, specific functions, molecular characteristics, genomic alterations, expression profiles, and tumor microenvironment of primary tumors. Tumoroids in vitro serve as an important component of the pipeline for the discovery of potential therapeutic targets and the identification of novel compounds. In this review, we will summarize recent advances in tumoroid cultures as an excellent tool for accurate cancer modeling. Additionally, vascularization and immune microenvironment modeling based on organoid technology will also be described. Furthermore, we will summarize the great potential of tumor organoids in predicting the therapeutic response, investigating resistance-related mechanisms, optimizing treatment strategies, and exploring potential therapies. In addition, the bottlenecks and challenges of current tumoroids will also be discussed in this review.

oncology,hematology
Organoids: An intermediate modeling platform in precision oncology.

Ming-Zhu Jin,Run-Run Han,Guan-Zhong Qiu,Xiang-Chun Ju,Ge Lou,Wei-Lin Jin

DOI: https://doi.org/10.1016/j.canlet.2017.11.021

IF: 9.756

2017-01-01

Cancer Letters

Abstract:Cancer harbors variable heterogeneity and plasticity. Thus far, our comprehension is greatly based on cell lines, organoids, and patient-derived tumor xenografts (PDTXs). Organoids are a three-dimensional in vitro culture platform constructed from self-organizing stem cells. They can almost accurately recapitulate tumor heterogeneity and microenvironment "in a dish," which surpass established cell lines and are not as expensive and time-consuming as PDTXs. As an intermediate model, tumor organoids are also used to study the fundamental issues of tumorigenesis and metastasis. They are specifically applied for drug testing and stored as "living biobanks." In this review, we highlight the translational applications of organoid technologies in tumor research and precision medicine, discuss the advantages and limitations compared with other mentioned methods, and provide our outlook on its future.
Genomic and Epigenomic Characterization of Tumor Organoid Models

Chehyun Nam,Benjamin Ziman,Megha Sheth,Hua Zhao,De-Chen Lin

DOI: https://doi.org/10.3390/cancers14174090

2022-08-25

Cancers

Abstract:Tumor organoid modeling has been recognized as a state-of-the-art system for in vitro research on cancer biology and precision oncology. Organoid culture technologies offer distinctive advantages, including faithful maintenance of physiological and pathological characteristics of human disease, self-organization into three-dimensional multicellular structures, and preservation of genomic and epigenomic landscapes of the originating tumor. These features effectively position organoid modeling between traditional cell line cultures in two dimensions and in vivo animal models as a valid, versatile, and robust system for cancer research. Here, we review recent advances in genomic and epigenomic characterization of tumor organoids and the novel findings obtained, highlight significant progressions achieved in organoid modeling of gene–drug interactions and genotype–phenotype associations, and offer perspectives on future opportunities for organoid modeling in basic and clinical cancer research.

oncology
Tumor organoids: From inception to future in cancer research

Liang Yang,Shuo Yang,Xinyu Li,Bowen Li,Yan Li,Xiaodong Zhang,Yingbo Ma,Xueqiang Peng,Hongyuan Jin,Qing Fan,Shibo Wei,Jingang Liu,Hangyu Li

DOI: https://doi.org/10.1016/j.canlet.2019.04.005

2019-07-10

Abstract:Tumor models have created new avenues for personalized medicine and drug development. A new culture model derived from a three-dimensional system, the tumor organoid, is gradually being used in many fields. An organoid can simulate the physiological structure and function of tissue in situ and maintain the characteristics of tumor cells in vivo, overcoming the disadvantages of traditional experimental tumor models. Organoids can mimic pathological features of tumors and maintain genetic stability, making them suitable for both molecular mechanism studies and pharmacological experiments of clinical transformation. In addition, the application of tumor organoids combined with other technologies, such as liquid biopsy technology, microraft array (MRA), and high-content screening (HCS), for the development of personalized diagnosis and cancer treatment has a promising future. In this review, we introduce the evolution of organoids and discuss their specific application and advantages. We also summarize the characteristics of several tumor organoids culture systems.
Advancing cancer research through organoid technology

Guolong Zeng,Yifan Yu,Meiting Wang,Jiaxing Liu,Guangpeng He,Sixuan Yu,Huining Yan,Liang Yang,Hangyu Li,Xueqiang Peng

DOI: https://doi.org/10.1186/s12967-024-05824-1

IF: 8.44

2024-11-10

Journal of Translational Medicine

Abstract:The complexity of tumors and the challenges associated with treatment often stem from the limitations of existing models in accurately replicating authentic tumors. Recently, organoid technology has emerged as an innovative platform for tumor research. This bioengineering approach enables researchers to simulate, in vitro, the interactions between tumors and their microenvironment, thereby enhancing the intricate interplay between tumor cells and their surroundings. Organoids also integrate multidimensional data, providing a novel paradigm for understanding tumor development and progression while facilitating precision therapy. Furthermore, advancements in imaging and genetic editing techniques have significantly augmented the potential of organoids in tumor research. This review explores the application of organoid technology for more precise tumor simulations and its specific contributions to cancer research advancements. Additionally, we discuss the challenges and evolving trends in developing comprehensive tumor models utilizing organoid technology.

medicine, research & experimental
Organoid cultures for the analysis of cancer phenotypes

Norman Sachs,Hans Clevers

DOI: https://doi.org/10.1016/j.gde.2013.11.012

2014-02-01

Abstract:Preclinical models of cancer are essential for a basic understanding of cancer biology and its translation into efficient treatment options for affected patients. Cancer cell lines and xenografts derived directly from primary human tumors have proven very valuable in fundamental oncology research and anticancer drug discovery. Both models inherently comprise advantages and caveats that have to be accounted for. We will outline in these and discuss primary patient derived organoids as third preclinical cancer model. We propose that cancer organoids could potentially fill the gap between simple cancer cell lines suitable for high-throughput screens and complicated, but physiologically relevant xenografts. The resulting applications for cancer organoids range from basic research to drug screens and patient stratification.

cell biology,genetics & heredity
Next-generation cancer organoids

Bauer L. LeSavage,Riley A. Suhar,Nicolas Broguiere,Matthias P. Lutolf,Sarah C. Heilshorn

DOI: https://doi.org/10.1038/s41563-021-01057-5

IF: 41.2

2021-08-12

Nature Materials

Abstract:Organotypic models of patient-specific tumours are revolutionizing our understanding of cancer heterogeneity and its implications for personalized medicine. These advancements are, in part, attributed to the ability of organoid models to stably preserve genetic, proteomic, morphological and pharmacotypic features of the parent tumour in vitro, while also offering unprecedented genomic and environmental manipulation. Despite recent innovations in organoid protocols, current techniques for cancer organoid culture are inherently uncontrolled and irreproducible, owing to several non-standardized facets including cancer tissue sources and subsequent processing, medium formulations, and animal-derived three-dimensional matrices. Given the potential for cancer organoids to accurately recapitulate the intra- and intertumoral biological heterogeneity associated with patient-specific cancers, eliminating the undesirable technical variability accompanying cancer organoid culture is necessary to establish reproducible platforms that accelerate translatable insights into patient care. Here we describe the current challenges and recent multidisciplinary advancements and opportunities for standardizing next-generation cancer organoid systems.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter
Advances and Applications of Cancer Organoids in Drug Screening and Personalized Medicine

DOI: https://doi.org/10.1007/s12015-024-10714-6

2024-03-28

Stem Cell Reviews and Reports

Abstract:In recent years, the rapid emergence of 3D organoid technology has garnered significant attention from researchers. These miniature models accurately replicate the structure and function of human tissues and organs, offering more physiologically relevant platforms for cancer research. These intricate 3D structures not only serve as promising models for studying human cancer, but also significantly contribute to the advancement of various potential applications in the field of cancer research. To date, organoids have been efficiently constructed from both normal and malignant tissues originating from patients. Using such bioengineering platforms, simulations of infections and cancer processes, mutations and carcinogenesis can be achieved, and organoid technology is also expected to facilitate drug testing and personalized therapies. In conclusion, regenerative medicine has the potential to enhance organoid technology and current transplantation treatments by utilizing genetically identical healthy organoids as substitutes for irreversibly deteriorating diseased organs. This review explored the evolution of cancer organoids and emphasized the significant role these models play in fundamental research and the advancement of personalized medicine in oncology.

cell biology,medicine, research & experimental,cell & tissue engineering
Complex in vitro 3D models of digestive system tumors to advance precision medicine and drug testing: Progress, challenges, and trends

Sheng-Lei Song,Bo Li,Mariana R. Carvalho,Hui-Jin Wang,De-Li Mao,Ji-Tao Wei,Wei Chen,Zhi-Hui Weng,Yang-Chao Chen,Chu-Xia Deng,Rui L. Reis,Joaquim M. Oliveira,Yu-Long He,Le-Ping Yan,Chang-Hua Zhang

DOI: https://doi.org/10.1016/j.pharmthera.2022.108276

IF: 13.4

2022-01-01

Pharmacology & Therapeutics

Abstract:Digestive system cancers account for nearly half of all cancers around the world and have a high mortality rate. Cell culture and animal models represent cornerstones of digestive cancer research. However, their ability to en-able cancer precision medicine is limited. Cell culture models cannot retain the genetic and phenotypic heteroge-neity of tumors and lack tumor microenvironment (TME). Patient-derived xenograft mouse models are not suitable for immune-oncology research. While humanized mouse models are time-and cost-consuming. Suitable preclinical models, which can facilitate the understanding of mechanisms of tumor progression and develop new therapeutic strategies, are in high demand. This review article summarizes the recent progress on the establish-ment of TME by using tumor organoid models and microfluidic systems. The main challenges regarding the translation of organoid models from bench to bedside are discussed. The integration of organoids and a microflu-idic platform is the emerging trend in drug screening and precision medicine. A future prospective on this field is also provided.(c) 2022 Published by Elsevier Inc.
Complex in vitro 3D models of digestive system tumors to advance precision medicine and drug testing: Progress, challenges, and trends

Sheng-Lei Song,Bo Li,Mariana R. Carvalho,Hui-Jin Wang,De-Li Mao,Ji-Tao Wei,Wei Chen,Zhi-Hui Weng,Yang-Chao Chen,Chu-Xia Deng,Rui L. Reis,Joaquim M. Oliveira,Yu-Long He,Le-Ping Yan,Chang-Hua Zhang

DOI: https://doi.org/10.1016/j.pharmthera.2022.108276

2022-11-01

Abstract:Digestive system cancers account for nearly half of all cancers around the world and have a high mortality rate. Cell culture and animal models represent cornerstones of digestive cancer research. However, their ability to enable cancer precision medicine is limited. Cell culture models cannot retain the genetic and phenotypic heterogeneity of tumors and lack tumor microenvironment (TME). Patient-derived xenograft mouse models are not suitable for immune-oncology research. While humanized mouse models are time- and cost-consuming. Suitable preclinical models, which can facilitate the understanding of mechanisms of tumor progression and develop new therapeutic strategies, are in high demand. This review article summarizes the recent progress on the establishment of TME by using tumor organoid models and microfluidic systems. The main challenges regarding the translation of organoid models from bench to bedside are discussed. The integration of organoids and a microfluidic platform is the emerging trend in drug screening and precision medicine. A future prospective on this field is also provided.

pharmacology & pharmacy
Organoid Models of Gastrointestinal Neoplasms: Origin, Current Status and Future Applications in Personalized Medicine

Yi Pan,Shuliang Zhao,Zhijun Cao

DOI: https://doi.org/10.1016/j.gendis.2018.09.002

IF: 7.376

2018-01-01

Genes & Diseases

Abstract:The in vitro organoid model is a major technological breakthrough that has been established as an important tool in many basic biological and clinical applications. This near-physiological 3D culture system accurately models various biological processes, including tissue renewal, stem cell/niche functions and tissue responses to drugs, mutations or damage. Organoids have the potential value of being an accurate model for disease predictions or drug screening applications and to identify the ideal treatment for that patient. Carcinogenesis can be modeled by mutating specific cancer genes in wild-type organoids; and patient-derived organoids provide an important resource in the development of personalized cancer treatment. Organoids from cancer patients could be used to identify the ideal treatment for a specific patient by growing matched healthy and diseased organoids from human cancer patients which additionally enables clinical screens for drug combinations. Organoids could also provide autologous cells or—in the future—tissue for transplantation. In this review, we discuss the current advances, challenges and potential applications of this technique in gastrointestinal neoplasms.
Organoid and Spheroid Tumor Models: Techniques and Applications

Sreenivasulu Gunti,Austin T.K. Hoke,Kenny P. Vu,Nyall R. London

DOI: https://doi.org/10.3390/cancers13040874

2021-02-19

Cancers

Abstract:Techniques to develop three-dimensional cell culture models are rapidly expanding to bridge the gap between conventional cell culture and animal models. Organoid and spheroid cultures have distinct and overlapping purposes and differ in cellular sources and protocol for establishment. Spheroids are of lower complexity structurally but are simple and popular models for drug screening. Organoids histologically and genetically resemble the original tumor from which they were derived. Ease of generation, ability for long-term culture and cryopreservation make organoids suitable for a wide range of applications. Organoids-on-chip models combine organoid methods with powerful designing and fabrication of micro-chip technology. Organoid-chip models can emulate the dynamic microenvironment of tumor pathophysiology as well as tissue–tissue interactions. In this review, we outline different tumor spheroid and organoid models and techniques to establish them. We also discuss the recent advances and applications of tumor organoids with an emphasis on tumor modeling, drug screening, personalized medicine and immunotherapy.

oncology
Patient-derived organoids in precision cancer medicine

Le Tong,Weiyingqi Cui,Boya Zhang,Pedro Fonseca,Qian Zhao,Ping Zhang,Beibei Xu,Qisi Zhang,Zhen Li,Brinton Seashore-Ludlow,Ying Yang,Longlong Si,Andreas Lundqvist

DOI: https://doi.org/10.1016/j.medj.2024.08.010

2024-11-08

Med

Abstract:Organoids are three-dimensional (3D) cultures, normally derived from stem cells, that replicate the complex structure and function of human tissues. They offer a physiologically relevant model to address important questions in cancer research. The generation of patient-derived organoids (PDOs) from various human cancers allows for deeper insights into tumor heterogeneity and spatial organization. Additionally, interrogating non-tumor stromal cells increases the relevance in studying the tumor microenvironment, thereby enhancing the relevance of PDOs in personalized medicine. PDOs mark a significant advancement in cancer research and patient care, signifying a shift toward more innovative and patient-centric approaches. This review covers aspects of PDO cultures to address the modeling of the tumor microenvironment, including extracellular matrices, air-liquid interface and microfluidic cultures, and organ-on-chip. Specifically, the role of PDOs as preclinical models in gene editing, molecular profiling, drug testing, and biomarker discovery and their potential for guiding personalized treatment in clinical practice are discussed.
Organoid Technology and Clinical Applications in Digestive System Cancer

Xiaofang Zhao,Youhai Jiang,Chunliang Liu,Minghui Hou,Hongyang Wang,Jing Fu

DOI: https://doi.org/10.1016/j.eng.2021.04.017

IF: 12.834

2022-01-01

Engineering

Abstract:Cancers of the digestive system(DS),including esophageal,gastric,colorectal,liver,and pancreatic can-cers,have a high incidence and mortality worldwide.Current cancer models cannot faithfully recapitu-late the critical features of the original tumor,resulting in the failure of translation from basic research into clinical practice.More advanced cancer models are in urgent need of pathogenesis exploration and anticancer medicine development.Organoids are in vitro cultured three dimensional(3D)self-organizing organotypic structures derived from tissues and pluripotent stem cells,which faithfully mimic the histological features and preserve the genetic heterogeneity of the original tissues.Both normal and malignant organoids can now be efficiently established from the DS tissues of patients.In this review,we summarize the general methods to generate human DS organoids and their applications as a novel model in basic cancer research,preclinical medical practice,and precision medicine.

Organoid modeling for cancer precision medicine

Cancer modeling meets human organoid technology

Cancer organoid co-culture model system: Novel approach to guide precision medicine

The power and the promise of organoid models for cancer precision medicine with next-generation functional diagnostics and pharmaceutical exploitation

Organoid co-culture models of the tumor microenvironment promote precision medicine

Organoids: approaches and utility in cancer research

Organoids for Cancer Research: Advances and Challenges

Tumor organoids: applications in cancer modeling and potentials in precision medicine

Organoids: An intermediate modeling platform in precision oncology.

Genomic and Epigenomic Characterization of Tumor Organoid Models

Tumor organoids: From inception to future in cancer research

Advancing cancer research through organoid technology

Organoid cultures for the analysis of cancer phenotypes

Next-generation cancer organoids

Advances and Applications of Cancer Organoids in Drug Screening and Personalized Medicine

Complex<i> in</i><i> vitro</i> 3D models of digestive system tumors to advance precision medicine and drug testing: Progress, challenges, and trends

Complex in vitro 3D models of digestive system tumors to advance precision medicine and drug testing: Progress, challenges, and trends

Organoid Models of Gastrointestinal Neoplasms: Origin, Current Status and Future Applications in Personalized Medicine

Organoid and Spheroid Tumor Models: Techniques and Applications

Patient-derived organoids in precision cancer medicine

Organoid Technology and Clinical Applications in Digestive System Cancer